BioCentury
ARTICLE | Company News

EMA to review Lundbeck's vortioxetine

September 21, 2012 12:29 AM UTC

H. Lundbeck A/S (CSE:LUN) said EMA accepted for review an MAA for vortioxetine ( Lu AA21004) to treat major depressive disorder (MDD). Lundbeck also said it and partner Takeda Pharmaceutical Co. Ltd. ...